Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo

CEPI pledged $60 million to develop vaccines against Bundibugyo ebolavirus. Moderna received $50 million for preclinical development and Phase 1 testing of its mRNA-based vaccine. The vaccine uses Moderna's mRNA platform, which enabled rapid COVID-19 vaccine development.